| mRNA |
Sorafenib |
CCLE |
pan-cancer |
AAC |
-0.0087 |
0.8 |
| mRNA |
crizotinib:PLX-4032 (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0063 |
0.9 |
| mRNA |
AZD-2281 |
CTRPv2 |
pan-cancer |
AAC |
-0.0063 |
0.9 |
| mRNA |
AA-COCF3 |
CTRPv2 |
pan-cancer |
AAC |
-0.0064 |
0.9 |
| mRNA |
ML334 diastereomer |
CTRPv2 |
pan-cancer |
AAC |
0.008 |
0.9 |
| mRNA |
KW-2449 |
CTRPv2 |
pan-cancer |
AAC |
-0.0053 |
0.9 |
| mRNA |
Methotrexate |
GDSC1000 |
pan-cancer |
AAC |
-0.0052 |
0.9 |
| mRNA |
BRD-K27188169:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0089 |
0.9 |
| mRNA |
GSK-J4 |
CTRPv2 |
pan-cancer |
AAC |
0.025 |
0.9 |
| mRNA |
JQ12 |
GDSC1000 |
pan-cancer |
AAC |
-0.0059 |
0.9 |